Drug intelligence / Profile preview

low-titer group O+ whole blood

Development stage
Unknown
Lead developer
American Red Cross
Modality
Tissue Cells → Other Cell Types → Cell Therapies, Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Low-titer group O+ whole blood (LTOWB) is a transfusion product consisting of unseparated, cold-stored human donor blood from individuals with type O positive (O+) blood and low levels of anti-A and anti-B antibodies. It contains all major components of circulating human blood—red cells, platelets, and plasma—in a single unit. The "low-titer" designation refers to the reduced concentration of naturally occurring anti-A and anti-B antibodies in the plasma portion (commonly defined as less than 1:200 or similar thresholds), which minimizes the risk of hemolytic reactions when transfused into recipients with different ABO types. LTOWB is primarily used for rapid resuscitation in trauma or massive hemorrhage situations where time is critical and crossmatching may not be feasible. Its mechanism is to restore circulating volume, oxygen-carrying capacity, coagulation factors, and platelets simultaneously—addressing both shock and coagulopathy in bleeding patients[1][4][5][6]. The use of RhD-positive units is common due to supply constraints; while this can theoretically cause alloimmunization in RhD-negative recipients (especially females of childbearing age), the risk is considered acceptable in life-threatening emergencies[7].

Other names
low titer O positive whole bloodLTOWBlow titer group O whole bloodlow titer type O whole blood

Beyond the preview

Go deeper on low-titer group O+ whole blood.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on low-titer group O+ whole blood.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call